Acquired Aplastic Anemia Market Information: By Type (Moderate Aplastic Anemia), By Diagnosis (Bone Marrow Biopsy, CT Scan), Treatment (Bone Marrow Transplantation, Immunosuppressive Therapies), End User (Hospitals & Clinics) - Forecast till 2030

ID: MRFR/Pharma/3249-HCR | 115 Pages | Published By Rahul Gotadki on March 2023

Acquired Aplastic Anemia Market Scenario

The global acquired aplastic anemia market is expected to reach USD 10,246.1 Million by 2030 at 4.20% CAGR during the forecast period 2022-2030Acquired aplastic anemia is a rare, serious blood disorder, which is characterized by failure of the bone marrow and its inability to produce blood cells. Bone marrow is found in the center of the bones and appears to be like a spongy substance. It is responsible for the production of red blood cells along with other blood components.

Aplastic anemia has two manifestations, i.e. Acquired aplastic anemia and inherit aplastic anemia Acquired aplastic anemia is more common, and sometimes it's only temporary whereas, it is a rare disorder as compared to inherit aplastic anemia. Various causes of acquired aplastic anemia includes toxins, such as pesticides, arsenic, and benzene, radiation and chemotherapy-treatments, infectious diseases, such as hepatitis, Epstein-Barr virus, cytomegalovirus, parvovirus B19, and HIV. And autoimmune disorders, such as lupus and rheumatoid arthritis. Sometimes, cancer from another part of the body can spread to the bone and cause acquired aplastic anemia.

The acquired aplastic anemia market growth is majorly attributed to the increasing prevalence of the blood disorders, rising funding, healthcare insurance coverage, and awareness programs for blood disorders.

According to the 2014 Annual Global Survey of the World Federation of Hemophilia (WFH), the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with Von Willebrand disease, and 1,123 with other blood disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years

A research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia and most dominant in male patients is 1: 5000 to 10,000. Whereas, the prevalence rate of hemophilia B is 1: 34,500 male patients.

Moreover, advancing technology in medical devices is adding fuel to the growth of the market. Furthermore, increasing prevalence of cancer also drives the market growth.

However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.

Figure: Global Acquired Aplastic Anemia Market, By Region Market Share, 2016 (%)

Sources: Annual reports, Press release, White paper, Company presentation

Acquired Aplastic Anemia Market Segmentations

The global acquired aplastic anemia market is segmented on the basis of types, by diagnosis, by treatment, and by end user.

On the basis of type, it is segmented into moderate aplastic anemia, severe aplastic anemia, and very severe aplastic anemia.

On the basis of diagnosis, it is segmented into bone marrow biopsy, X-rays, computed tomography (CT) scans, and others.

On the basis of treatment, it is segmented into bone marrow transplantation, immunosuppressive therapies, and others.

On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.

Acquired Aplastic Anemia Market Regional Analysis

The Americas dominate the global acquired aplastic anemia market owing to well-developed technology, increasing patient with blood disorders, increasing prevalence of cancer, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global acquired aplastic anemia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.

Asia Pacific is the fastest growing acquired aplastic anemia market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the acquired aplastic anemia in the region.

On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.

Acquired Aplastic Anemia Market Key Players

Some of key the players in the acquired aplastic anemia market are

Pfizer Inc. (U.S.)

Bayer AG (Germany)

Novo Nordisk AS (Dernmark)

Shire (Republic of Ireland)

SOBI (Sweden)

Octapharma (Switzerland)

CSL Limited (Australia)

Amgen Inc.

GlaxoSmithKline plc.

Bluebird bio.

Intended Audience

Pharmaceutical Companies

Medical Devices Companies

Research and Development (R&D) Companies

Government Research Institute

Academic Institutes and Universities

Research Methodology Acquired Aplastic Anemia Market-

Sources: Annual reports, Press release, White paper, and Company presentation

Report Scope:

Report Attribute/Metric	Details
Market Size	2030: USD 10,246.1 Million
CAGR	2022-2030: 4.20%
Base Year	2021
Forecast Period	2030
Historical Data	2020
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Types, Diagnosis, Treatment, And End User
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), CSL Limited (Australia), Amgen Inc., GlaxoSmithKline plc., and Bluebird bio.
Key Market Opportunities	High healthcare spending Increasing government support for research & development
Key Market Drivers	Increasing prevalence of the blood disorders Rising funding Healthcare insurance coverage Awareness programs for blood disorders

Speak to Analyst Ask for Customization